A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot

Exclusion Criteria

• •Evidence of a trial fibrillation/flutter or chemotherapy/radiation therapy for malignancy (other than non-melanoma skin cancer) during 6-month period preceding first receipt of index therapy
• •Evidence of VTE(VTE event)during 6-month period preceding index encounter
• •Evidence of malignancy (other than non-melanoma skin cancer) during 90-day period preceding first receipt of index therapy